Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Histone deacetylases (HDACs) enzymes, which affect the acetylation status of histones and other important cellular proteins, have been recognized as potentially useful therapeutic targets for a broad range of human disorders. Emerging studies have demonstrated that different types of HDAC inhibitors show beneficial effects in various experimental models of neurological disorders. HDAC enzymes comprise a large family of proteins, with18 HDAC enzymes currently identified in humans. Hence, an important question for HDAC inhibitor therapeutics is which HDAC enzyme(s) is/are important for the amelioration of disease phenotypes, as it has become clear that individual HDAC enzymes play different biological roles in the brain. This review will discuss evidence supporting the involvement of HDAC1 and HDAC3 in polyglutamine disorders, including Huntington’s disease, and the use of HDAC1- and HDAC3-selective HDAC inhibitors as therapeutic intervention for these disorders. Further, while HDAC inhibitors are known alter chromatin structure resulting in changes in gene transcription, understanding the exact mechanisms responsible for the preclinical efficacy of these compounds remains a challenge. The potential chromatin-related and non-chromatin-related mechanisms of action of selective HDAC inhibitors will also be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1
Orr, H. T., Chung, M.-Y., Banfi, S., Kwiatkowski, T. J., Servadio, A., Beaudet, A. L., McCall, A. E., Duvick, L. A., Ranum, L. P. W., & Zoghbi, H. Y. (1993) · Nature Genetics · doi:10.1038/ng0793-221 · Cited by 1,632 · cited 1×
“Spinocerebellar ataxia 1 (SCA1) is caused by glutamine repeat expansion in the ataxin 1 (ATXN1) gene [73].”
BackgroundAcetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584 · cited 1×
“Accumulating evidence suggests that many HDACs, including class I HDACs, can also deacetylate non-histone proteins [114], which may contribute to their beneficial properties.”
BackgroundHistone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542 · cited 3×
“Class I HDACs consists of HDACs 1, 2, 3 and 8, while class II HDACs are divided into two groups: class IIa, consisting of HDACs 4, 5, 7 and 9, and class IIb, consisting of HDACs 6 and 10 [5].”
BackgroundGregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila
Steffan, J. S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B. L., Kazantsev, A., Schmidt, E., Zhu, Y.-Z., Greenwald, M., et al. (2001) · Nature · doi:10.1038/35099568 · Cited by 1,228 · cited 1×
“cause both up- and down-regulation of gene expression patterns, with little predictive value [60,92,113].”
BackgroundDompierre, J. P., Godin, J. D., Charrin, B. C., Cordelières, F. P., King, S. J., Humbert, S., & Saudou, F. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0037-07.2007 · Cited by 792
Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression
Lagger, G., O'Carroll, D., Rembold, M., Khier, H., Tischler, J., Weitzer, G., Schuettengruber, B., Hauser, C., Brunmeir, R., Jenuwein, T., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/21.11.2672 · Cited by 760 · cited 3×
“The Sin3 and the NuRD complexes are broadly-acting modulators of gene transcription [26,27] and bind a spectrum of different cofactors such as SAP proteins, Mi2, MTA2, and MBD proteins [18,25,28,29].”
BackgroundResultFischle, W., Dequiedt, F., Hendzel, M. J., Guenther, M. G., Lazar, M. A., Voelter, W., & Verdin, E. (2002) · Molecular Cell · doi:10.1016/s1097-2765(01)00429-4 · Cited by 754 · cited 3×
“NCoR/SMRT complexes [44–46].”
BackgroundGao, L., Cueto, M. A., Asselbergs, F., & Atadja, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111871200 · Cited by 744 · cited 1×
“Class IV is represented by a single member, HDAC11 [14], and while sharing similar characteristics to HDACs in classes I and II, HDAC 11 is thought to have a distinct physiological role [14,15].”
BackgroundChemical phylogenetics of histone deacetylases
Bradner, J. E., West, N., Grachan, M. L., Greenberg, E. F., Haggarty, S. J., Warnow, T., & Mazitschek, R. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.313 · Cited by 720 · cited 1×
“binding proteins, that recruit HDAC3 to active chromatin in order to alter gene transcription [47].”
BackgroundDetermination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070779 · Cited by 713
Identification of genes that modify ataxin-1-induced neurodegeneration
Fernandez-Funez, P., Nino-Rosales, M. L., de Gouyon, B., She, W.-C., Luchak, J. M., Martinez, P., Turiegano, E., Benito, J., Capovilla, M., Skinner, P. J., et al. (2000) · Nature · doi:10.1038/35040584 · Cited by 661
HDAC1 and HDAC2 regulate oligodendrocyte differentiation by disrupting the β-catenin–TCF interaction
Ye, F., Chen, Y., Hoang, T., Montgomery, R. L., Zhao, X.-H., Bu, H., Hu, T., Taketo, M. M., van Es, J. H., Clevers, H., et al. (2009) · Nature Neuroscience · doi:10.1038/nn.2333 · Cited by 559 · cited 1×
“HDAC1 is expressed primarily in neurons but also in glial cells, including astrocytes [32,34] and oligodendrocytes, where it is required for formation and differentiation [35].”
BackgroundHDAC3 Is a Critical Negative Regulator of Long-Term Memory Formation
McQuown, S. C., Barrett, R. M., Matheos, D. P., Post, R. J., Rogge, G. A., Alenghat, T., Mullican, S. E., Jones, S., Rusche, J. R., Lazar, M. A., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5052-10.2011 · Cited by 507
Global changes to the ubiquitin system in Huntington's disease
Bennett, E. J., Shaler, T. A., Woodman, B., Ryu, K.-Y., Zaitseva, T. S., Becker, C. H., Bates, G. P., Schulman, H., & Kopito, R. R. (2007) · Nature · doi:10.1038/nature06022 · Cited by 497 · cited 1×
“play a role in neurodegenerative disorders, many of which are pathologically characterized by the presence of ubiquitin-positive protein aggregates, suggesting impairment of the ubiquitin-proteasome system [115,117–120].”
BackgroundHistone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia
Herman, D., Jenssen, K., Burnett, R., Soragni, E., Perlman, S. L., & Gottesfeld, J. M. (2006) · Nature Chemical Biology · doi:10.1038/nchembio815 · Cited by 442 · cited 2×
“Accordingly, studies have demonstrated that different types of HDAC inhibitors elevate histone acetylation on both local and/or global level [21,60,105,106], and microarray studies have demonstrated that HDAC inhibitors do indeed elicit effects on gene expression.”
BackgroundChen, X., Barozzi, I., Termanini, A., Prosperini, E., Recchiuti, A., Dalli, J., Mietton, F., Matteoli, G., Hiebert, S., & Natoli, G. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121131109 · Cited by 397 · cited 1×
“One study demonstrated that Hdac3(−/−) cells display greatly increased constitutive expression of Ptgs1 (COX-1), which encodes a key enzyme in the synthesis of prostaglandins and reactive electrophilic oxoderivatives (EFOXs), which show strong anti-inflammatory effects [141].”
BackgroundYasuda, S., Liang, M.-H., Marinova, Z., Yahyavi, A., & Chuang, D.-M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002099 · Cited by 358 · cited 2×
“In that study, Bdnf promoter IV activity was stimulated after transfection with an HDAC1-specific siRNA [130] and in HDAC1 siRNA-treated neurons, VPA failed to further enhance BDNF promoter IV activity.”
BackgroundHDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?
Simões-Pires, C., Zwick, V., Nurisso, A., Schenker, E., Carrupt, P.-A., & Cuendet, M. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-7 · Cited by 341
Deregulation of HDAC1 by p25/Cdk5 in Neurotoxicity
Kim, D., Frank, C. L., Dobbin, M. M., Tsunemoto, R. K., Tu, W., Peng, P. L., Guan, J.-S., Lee, B.-H., Moy, L. Y., Giusti, P., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.015 · Cited by 286
Human HDAC7 Histone Deacetylase Activity Is Associated with HDAC3in Vivo
Fischle, W., Dequiedt, F., Fillion, M., Hendzel, M. J., Voelter, W., & Verdin, E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104935200 · Cited by 232 · cited 3×
“NCoR/SMRT complexes [44–46].”
BackgroundPimelic Diphenylamide 106 Is a Slow, Tight-binding Inhibitor of Class I Histone Deacetylases
Chou, C. J., Herman, D., & Gottesfeld, J. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m807045200 · Cited by 223 · cited 13×
“This review has summarized the involvement of HDAC1 and HDAC3 in neurodegenerative processes and transcriptional dysregulation associated with different polyglutamine diseases, which has provided a basis for the use of selective HDAC inhibitors targeting these subtypes for therapeutic purposes.”
BackgroundInfluentialHistone Deacetylase 3 Interacts with and Deacetylates Myocyte Enhancer Factor 2
Grégoire, S., Xiao, L., Nie, J., Zhang, X., Xu, M., Li, J., Wong, J., Seto, E., & Yang, X.-J. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00882-06 · Cited by 203 · cited 1×
“Non-histone transcription factor targets for HDAC3 include Smad7, Myocyte enhancer factor 2 (MEF2), Mitogen-activated protein kinase phosphatase-1 (MKP-1), nuclear factor-kappaB (NFkB) [113,142–144], with two of these, MKP-1 and NFkB being implicated in inflammation.”
BackgroundRegulation of histone deacetylase 2 by protein kinase CK2
Tsai, S.-C., & Seto, E. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204149200 · Cited by 196 · cited 2×
“The Sin3 and the NuRD complexes are broadly-acting modulators of gene transcription [26,27] and bind a spectrum of different cofactors such as SAP proteins, Mi2, MTA2, and MBD proteins [18,25,28,29].”
BackgroundMielcarek, M., Landles, C., Weiss, A., Bradaia, A., Seredenina, T., Inuabasi, L., Osborne, G. F., Wadel, K., Touller, C., Butler, R., et al. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001717 · Cited by 172
Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders
Grayson, D. R., Kundakovic, M., & Sharma, R. P. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.061333 · Cited by 171 · cited 2×
“A large majority of hydroxamate HDAC inhibitors act as pan-HDAC inhibitors, and do not show selectivity within the zinc dependent classes of HDAC enzymes [53]; however due to the large variation in chemical structure among peptides, peptide HDAC inhibitors can elicit inhibition of different HDAC isoforms, including mo…”
BackgroundNeuroprotection by histone deacetylase-related protein
Morrison, B. E., Majdzadeh, N., Zhang, X., Lyles, A., Bassel-Duby, R., Olson, E. N., & D'Mello, S. R. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.9.3550-3564.2006 · Cited by 100
Spinocerebellar ataxias caused by polyglutamine expansions: A review of therapeutic strategies
Underwood, B. R., & Rubinsztein, D. C. (2008) · The Cerebellum · doi:10.1007/s12311-008-0026-z · Cited by 44 · cited 3×
“Six of the spinocerebellar ataxias (SCAs) are classified as polyglutamine disorders [71]; hence, these are caused by expanded CAG repeats in the coding regions of the relevant disease genes.”
Background
Cited by
Kumar, V., Kundu, S., Singh, A., & Singh, S. (2022) · Current Neuropharmacology · doi:10.2174/1570159x19666210609160017 · Cited by 210
“present in neuronal cells like glial cells, including astrocytes and oligodendrocytes [33, 34].”
BackgroundAdhikari, N., Jha, T., & Ghosh, B. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01676 · Cited by 74
Small molecule modulators of chromatin remodeling: from neurodevelopment to neurodegeneration
Jiang, D., Li, T., Guo, C., Tang, T.-S., & Liu, H. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-00953-4 · Cited by 54
The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay
Xia, J., Hu, H., Xue, W., Wang, X. S., & Wu, S. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1437156 · Cited by 24
Metadata
- Authors
- Thomas, E.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2014-05-26
- Volume
- 7
- Issue
- 6
- Pages
- 634-661
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W2035896803
- Cited by
- 55
- References
- 28
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.